Table 1.
S. No | Comp | IC50 (10 µM) against the Selected Cell Lines | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
CaCo2 | DLD1 | HT-29 | HCT-15 | A172 | A549 | TERA-1 | MCF-7 | MDA-MB-231 | ||
1 | 15a | 4.9 | 20.6 | >20 | >20 | >20 | >20 | >20 | >20 | 14.5 |
2 | 15b | >20 | >20 | 3.71 | >20 | >20 | >20 | >20 | >20 | >20 |
3 | 15c | 11.9 | 7.3 | >20 | >20 | 16.6 | 7.8 | >20 | >20 | >20 |
4 | 15d | 4.5 | 16.5 | >20 | >20 | >20 | 17.9 | >20 | 3.36 | >20 |
5 | 15e | >20 | 18.9 | >20 | >20 | >20 | 17.5 | >20 | >20 | >20 |
6 | 15f | >20 | 8.1 | 2.98 | 2.64 | 12.3 | 5.02 | 4.8 | >20 | >20 |
7 | 15g | 6.9 | 7.2 | >20 | >20 | >20 | 7.0 | >20 | >20 | >20 |
8 | 15h | >20 | >20 | 5.85 | >20 | >20 | >20 | 17.4 | >20 | 1.35 |
9 | 15i | >20 | >20 | >20 | >20 | 10.7 | >20 | >20 | >20 | 3.16 |
10 | 15j | 8.9 | 13.3 | >20 | >20 | 17.3 | 10.0 | 17.5 | >20 | >20 |
11 | 15k | 12.3 | 8.2 | 3.73 | 1.37 | >20 | 8.9 | >20 | 3.85 | >20 |
12 | 15l | >20 | >20 | 6.44 | 3.20 | >20 | >20 | >20 | >20 | >20 |
13 | 15m | 8 | 8.9 | >20 | 12.42 | 14.7 | 13.7 | 17.7 | 2.29 | 6.11 |
14 | 15n | 12.1 | 9.3 | >20 | >20 | 15.9 | 10.5 | 14.1 | >20 | >20 |
15 | 15o | 5.1 | 5.6 | 2.04 | >20 | 4.4 | 5.7 | 5.1 | >20 | >20 |
16 | 15p | >20 | 19.1 | >20 | >20 | >20 | >20 | >20 | >20 | >20 |
17 | 15q | 14.4 | 8.9 | >20 | >20 | 18.9 | 9.3 | >20 | >20 | >20 |
18 | 15r | 6.5 | 7.9 | 0.85 | 4.04 | 8.8 | 7.4 | 8.4 | 3.03 | >20 |
19 | 5-FU | - | - | 5.31 | - | - | - | - | - | - |
The 50% inhibitory concentrations were the average values of three individual experiments in MCF-7 (breast cancer cell line), MDA-MB-231 (triple-negative breast cancer (TNBC) cell line), HT-29, DLD1, and CaCO2 (human colorectal adenocarcinoma cell line), HCT-15 (human colon adenocarcinoma colorectal adenocarcinoma), lung adenocarcinoma A549, glioblastoma, brain cancer A172, teratocarcinoma and testicular cancer TERA-1, and NRK 52E (normal rat kidney cell).